Financial PerformanceClover Health reported impressive 1Q'24 results with revenue of $346.9M, beating consensus expectations by 8% and improving its medical cost ratio significantly.
New Product LaunchClover Health's new clinical decision support technology, Counterpart Assistant, is being commercialized to external payers and providers, leveraging existing technology and customer service resources without significant investment.
Profitability OutlookClover Health raised its guidance to adjusted EBITDA of $10-30M and now expects to achieve break-even CFOps in 2024, signaling a more sustainable pathway for the company's future.